SynthesisRheumatology international2026
Beyond anti-SSA and anti-SSB. The clinical significance of new antibodies in the diagnosis of Sjögren disease.
Synthesis in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patterns of referral and histopathological interpretation of minor salivary gland biopsy in suspected Sjögren's disease: a single-center experience.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren disease (SjD) is a heterogeneous autoimmune disorder classically diagnosed based on the presence of characteristic autoantibodies. While anti-Ro/SSA and anti-La/SSB antibodies remain classical diagnostic markers, emerging studies have identified additional autoantibodies with potential diagnostic and prognostic value. This systematic review summarizes current evidence on both established and novel antibodies in SjD. A systematic literature review was performed using PubMed/MEDLINE and Scopus for studies published up to December 2025. Keywords combined terms related to SjD (primary, secondary, pSS, sSS, sicca) and autoantibodies (SSA, SSB, Ro52, Ro60, anti-M3R, anti-CA6, anti-PSP, anti-SP-1, anti-CEP-1, anti-AQP). Searches were limited to studies involving humans and publications in English. Editorials, commentaries, case reports, interventional studies, surveys, and questionnaires were excluded. Reference lists of included articles were manually screened to identify additional relevant publications. Classical antibodies (anti-Ro/SSA, anti-La/SSB) remain the primary biomarkers in the diagnostic process; however, disease course varies among patients according to the antibody profile (Ro52, Ro60, La), which correlates with distinct clinical phenotypes. Novel antibodies, including anti-CA6, anti-PSP, and anti-SP-1, show promise as early biomarkers, particularly in seronegative patients. Specific antibodies have also been associated with systemic organ involvement. The spectrum of autoantibodies in SjD supports the diagnostic process and provides insights into disease heterogeneity and prognosis. Incorporating emerging antibodies into diagnostic panels may facilitate early detection. Large-scale, standardized studies are needed to validate the clinical utility of these novel biomarkers.
Indexed as
Identifiers
41863568What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.